Alerta

ANTI-SARS-COV-2 MONOCLONAL ANTIBODY AND IMMUNOASSAY METHOD AND IMMUNOASSAY INSTRUMENT FOR SARS-COV-2 USING SAME

Resumen de: US20260226140A1

Disclosed are a monoclonal antibody capable of rapidly, simply, and highly sensitively detecting and measuring SARS-CoV-2 contained in a test sample, and an immunoassay method and immunoassay device for SARS-CoV-2 using the same. The monoclonal antibody or its antigen-binding fragment includes heavy chain CDR1-CDR3 having specific amino acid sequences and light chain CDR1-CDR3 having specific amino acid sequences. The immunoassay method for SARS-CoV-2 includes performing an immunoassay of SARS-CoV-2 utilizing an antigen-antibody reaction between this monoclonal antibody or its antigen-binding fragment and SARS-CoV-2 in a sample.

COLD-ADAPTED, LIVE ATTENUATED SARS-COV-2 VACCINE

Resumen de: US20260226425A1

An isolated nucleic acid comprising a recombinant coronavirus genome having a genetic modification that provides cold-adapted growth relative to a parent virus that is not cold-adapted and a vaccine comprising the recombinant genome and methods of using the vaccine are provided.

β-LACTOGLOBULIN FOR USE AS ANTIVIRAL AGENT

Resumen de: WO2026163139A1

The present disclosure relates to the use of β-lactoglobulin in the treatment of a viral condition, wherein β-lactoglobulin is in its native protein state, wherein the viral condition is caused by a human Rotavirus strain or Coronavirus OC43. The present disclosure further relates to a pharmaceutical composition comprising β-lactoglobulin and one or more pharmaceutically acceptable excipients, wherein the pharmaceutical composition further comprises at least one additional therapeutic agent.

SARS-COV2 MAIN PROTEASE INHIBITORS

Resumen de: AU2025219283A1

The present disclosure relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.

SARS-COV2 MAIN PROTEASE INHIBITORS

Resumen de: AU2025218930A1

The present disclosure relates to compounds of Formula I and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.

HUMAN ANTIBODIES TO MIDDLE EAST RESPIRATORY SYNDROME-RELATED CORONAVIRUS (MERS-CoV) AND METHODS OF USE THEREFOR

Resumen de: WO2026165023A1

The present disclosure is directed to antibodies binding to and neutralizing Middle East Respiratory Syndrome-Related Coronavirus (MERS-CoV) and methods for use thereof.

SARS-COV-2 REPLICATION-DEFECTIVE VIRUS SYSTEM

Resumen de: WO2026163027A1

Provided herein is a replication-defective coronavirus having in its genome a modification, wherein the modification results in a reduced expression of the M gene compared to a coronavirus lacking the modification.

ANTI-SARS-COV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19

Resumen de: CN122029189A

The present invention provides antibodies that bind to the SARS-CoV-2 spike (S) protein. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions and methods of using the above antibodies that bind to the SARS-CoV-2 spike (S) protein.

ANTIBODY SPECIFICALLY BINDING TO IL-10 RECEPTOR AND USE THEREOF

Resumen de: US20260217840A1

The present invention relates to an antibody specifically binding to an IL-10 receptor and use thereof. The antibody targets IL-10 signaling and has an excellent effect of suppressing cytokine storm and excessive inflammation in severe inflammatory infectious diseases, and in particular, can be effectively used in suppressing inflammatory responses in severe SARS-CoV-2 infection and fatal SFTSV infection.

CORONAVIRUS ANTIBODIES AND THERAPEUTIC USES THEREOF

Resumen de: US20260217797A1

Disclosed herein are antibodies that bind to coronavirus spike protein (e.g., SARS-CoV-2 spike protein), and methods of use thereof (e.g., treatment of subjects infected with SARSCoV-2).

A method of preventing and treating disease with transformed microbes

Resumen de: US20260216253A1

The covid-19 coronavirus has killed more than 5,129,829 people, globally, out of about 255,098,687 infected. About 10 million persons died from cancer in 2020, with 19.3 new cases diagnosed. About 409,000 persons died of malaria in 2019. And none of these diseases made the WHO's list of top 5 deadly diseases of 2019. Modern medicine has made tremendous progress in the prevention and treatment of disease, but the crashing of the covid-19 coronavirus and the extremely high burden of the top deadly diseases point to the urgency of radical and totally disrupting inventions in medicine. Indeed, to effectively overcome the current burden of deadly diseases we need an agile platform with exponentially better efficacy and predictability. The world is in dire need of a new medicine platform that totally and radically disrupts the current healthcare systems and the traditional ways of preventing and treating disease. The present invention does that.The present invention uses transformed microbes, targeted to one or more mucosal surface, to prevent and treat just about any disease of importance. The current means of disease prevention relies on vaccines. As we have seen from countless failures and booster shots, vaccines have extreme limitations and increasingly fewer following. Firstly, vaccine development is unpredictable, lengthy and costly. An important lesson of the covid-19 pandemic is that waiting for several months or years to develop a vaccine, while a disease ravages the popul

TREATMENT OF CHEMOSENSORY DYSFUNCTION FROM A CORONAVIRUS INFECTION

Resumen de: US20260216194A1

Disclosed herein are methods of treating a taste and smell disorder caused by a viral infection in a subject, comprising administering to the subject a phosphodiesterase inhibitor. Also disclosed herein are methods of treating taste and smell loss from COVID-19 by administering a phosphodiesterase inhibitor to a subject in need thereof.

Treatment of symptomatic viral disease

Resumen de: AU2026205425A1

Abstract Provided is a composition comprising a phenyl pyrrole aminoguanidine derivative for use in a method of treating viral disorders and diseases, including symptomatic viral disorders and diseases, including symptomatic COVID-19. 5 Abstract ul b s t r a c t u l

MEMBRANE-BASED, IN-GEL LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) SYSTEM AND METHOD FOR DETECTING MICROBES

Resumen de: ZA202304107B

Disclosed herein is a membrane-based, in-gel loop-mediated isothermal amplification (LAMP) system, kit and method for detection of a target microorganism in a sample suspected of containing the microorganism. LAMP reagents, a lysing agent and a hydrogel are placed together on a filter membrane loaded with a pre-filtered sample. The hydrogel polymerizes over a short time to immobilize any target DNA/RNA particles on the membrane. The system may include a compact, portable device that integrates heat incubation and fluorescence illumination, and also a cloud-based smartphone image analysis application for quantitative results interpretation. If target DNA/RNA are present in the sample, fluorescent amplicons are produced as a result of LAMP reaction. The target microorganisms are detected by visually detecting the presence or absence of the amplicons. The method may be employed for rapid and inexpensive point-of-use (POU) absolute quantification of SARS-CoV-2 in environmental water or wastewater samples with high sensitivity.

Voice amplifier that amplifies a human voice from a microphone through a mobile device and internal speaker

Resumen de: US12695826B1

A voice amplifier that amplifies volume of a human voice from a microphone through a mobile device by utilizing a speaker that is communicably connected to the mobile device is disclosed. The voice amplifier is designed for a mobile device, such as a smart phone or a tablet computing device. The voice amplifier purely amplifies the voice from a wired or non-wired microphone through a phone operating system and hardware components and other modules of the mobile device, such as by utilizing the phone speaker and/or an optional wireless or wired speaker. Essentially through a voice amplifier mobile app, a voice can be amplified simply with the touch of one icon. The concept is for people wearing masks due to COVID-19 and future other viruses, and/or dusty, toxic, or otherwise unhealthy air environments where masks are needed, to continue to wear their mask but be able to communicate clearly.

Methods for Bicameral, CNS+ Treatment of CNS, Cardiovascular, Metabolic and Other Disorders

Resumen de: US20260207714A1

0000 Safe, effective, disease-modifying treatments—and especially, optimized treatments—for Alzheimer's and many other CNS, cardiovascular, metabolic and other disorders remain elusive. This is in part due to many CNS, cardiovascular, metabolic. and other disorders having underlying components on both sides of the blood-brain barrier—e.g., having CNS components as well as cardiovascular and/or metabolic and/or other non-CNS components. Respective examples in CNS, cardiovascular, metabolic and other domains include Alzheimer's disease, heart failure, diabetes and COVID-19. This is in and of itself a challenge, as most drugs (~98% of small molecules; a greater portion of larger molecules such as antibodies and peptides) do not cross the blood brain barrier appreciably, and even when they do, the chances of them having a partition coefficient that optimizes dosing in compartments on both sides of the blood brain barrier is vanishingly low. This invention addresses that challenge with a novel, bicameral, CNS+ (i.e., two-compartment, where one compartment is on the neuronal/glial side of the blood-brain barrier and one compartment is not) approach. This bicameral, CNS+ approach involves parallel 1) Intranasal, direct-to-brain delivery of drugs addressing the CNS component of a CNS, cardiovascular or metabolic disorder 2) Delivery (oral, injection or otherwise) of a cardiovascular &/or metabolic &/or other agent to the central compartment (i.e., blood and well-perfused org

CRIPPLED CORONAVIRUS: 5'-POLYU TARGETED OLIGO PREVENTS DEVELOPMENT OF INFECTIOUS VIRIONS

Resumen de: US20260209766A1

0000 The present disclosure provides compositions and methods for treating and detecting coronavirus infection, and in particular, provides compositions and methods for treating and detecting SARS-CoV-2 infection. The present disclosure also relates to the production of compositions for treating and detecting coronavirus infection, and in particular, to the production of compositions for treating and detecting SARS-CoV-2 infection.

PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION

Resumen de: US20260209180A1

0000 The present invention provides a compound of Formula I wherein R<1>, R<2>, R<3>, R<4>, R<5>, R<6>, R<7>, and subscripts X and n are as described herein and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for the treatment, inhibition, or amelioration of one or more disease states that could benefit from inhibition of a coronavirus, including SARS-CoV, MERS-CoV and SARS-CoV-2. The compounds of this invention could further be used in combination with other therapeutically effective agents, including but not limited to, other drugs useful for the treatment of coronavirus infection. The invention furthermore relates to processes for preparing compounds of Formula I, and pharmaceutical compositions which comprise compounds of Formula I and pharmaceutically acceptable salts thereof. 0000

MONOCLONAL ANTIBODIES FOR TREATING SARS-COV-2 INFECTION

Resumen de: US20260209317A1

Disclosed are monoclonal antibodies, antigen binding fragments, and multi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies and multi-specific antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies and multi-specific antibodies. In some aspects, the antibodies bind a BA.4 or BA.5 variant. In other aspects, the antibodies bind BQ1.1 and/or XBV.

SARS-COV-2 SPIKE PROTEIN-BINDING MOLECULES

Resumen de: US20260209318A1

SARS-CoV-2 spike protein-binding molecules are disclosed. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, and methods using, the SARS-CoV-2 spike protein-binding molecules.

SYSTEM AND METHOD FOR SCREENING RNA APTAMER

Resumen de: US20260209750A1

Disclosed is a CRISPR/Cas based system for screening an RNA aptamer against a target protein, comprising: (i) a guide RNA comprising a recognition sequence and a nucleic acid aptamer random library having a predetermined length; (ii) a target sequence complementary to the recognition sequence of the guide RNA; (iii) a selection marker located downstream of the target sequence and comprising a basal promoter and a selection marker gene; (iv) a fusion protein comprising the target protein and a transcriptional activation module, wherein a binding of the target protein to an RNA aptamer of the nucleic acid aptamer random library results in recruitment of the transcriptional activation module to the selection marker; (v) a dCas protein specifically recognizing the target sequence under the guidance of the guide RNA; and (vi) a screening cell. Also disclosed is a method for screening an RNA aptamer against a target protein using the system provided herein and RNA aptamers against S1 protein of SARS-CoV-2 virus and applications thereof.

Application of Shenling Baizhu in Preparation of Medicine for Treating Neuropsychiatric Symptoms of Recovered COVID-19 Patients

Resumen de: US20260207693A1

0000 An application of Shenling Baizhu in the preparation of a medicine for treating neuropsychiatric symptoms of recovered COVID-19 patients.

MULTIPLEXED COVID-19 PADLOCK ASSAY

Resumen de: US20260209831A1

Methods and systems for detecting the presence of a target nucleic acid sequence in one or more samples of a plurality of samples are described. The methods may comprise the use of linear barcoded nucleic acid probes that, upon hybridization to a target nucleic acid sequence, may be ligated to circularize the probe molecule, amplified, and sequenced. The use of a probe-specific barcode integrated into the nucleic acid probe molecule, and sample-specific barcodes that may be incorporated into the nucleic acid probe molecule or added during the amplification step, enable large-scale multiplexed assay and sample processing.

METHOD FOR TREATING RESPIRATORY VIRAL INFECTIONS COMPRISING ADMINISTRATION OF FATTY ACID COMPOSITIONS

Resumen de: US20260207541A1

0000 Methods and compositions comprising free fatty acids for the treatment, including prevention, of viral infections, including the treatment of Acute Respiratory Distress Syndrome (ARDS). The compositions comprising free fatty acids, optionally linolenic acid, linoleic acid, and/or palmitic acid, may be used in methods for treating viral infections, optionally, coronavirus infections, for example, SARS-CoV, MERS-CoV, and/or SARS-CoV-2/COVID-19, and influenza virus infections, optionally, H1N1 and/or H5N1.

TRANSMEMBRANE SERINE PROTEASE 2 (TMPRSS2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF

Nº publicación: US20260209778A1 23/07/2026

Solicitante:

ALNYLAM PHARMACEUTICALS INC [US]
Alnylam Pharmaceuticals, Inc.

Resumen de: US20260209778A1

0000 The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the transmembrane serine protein 2 (TMPRSS2) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a TMPRSS2 gene and to methods of treating or preventing a TMPRSS2-associated disease, e.g., COVID-19, in a subject.